2-Hydroxyanthraquinone

Synonyms: 2-羟基蒽醌
2-Hydroxyanthraquinone 是 Anthracene (ANT) (MS-U94791) 经光化学氧化作用生成的产物,它通过耗竭 GSH 和抑制 GPX4 诱发心肌细胞铁死亡 (ferroptosis) 致心脏发育畸形,并通过下调 Wnt/β-catenin 信号通路并诱导炎症和脑细胞凋亡 (apoptosis) 导致斑马鱼脑血管及血脑屏障损伤,可用于脑血管疾病与心脏毒性的相关研究。
产品编号: MS-K68123 纯度: 98.0% CAS No.: 605-32-3 分子式: C14H8O3 分子量: 224.22
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
询价

产品描述

2-Hydroxyanthraquinone 是 Anthracene (ANT) (MS-U94791) 经光化学氧化作用生成的产物,它通过耗竭 GSH 和抑制 GPX4 诱发心肌细胞铁死亡 (ferroptosis) 致心脏发育畸形,并通过下调 Wnt/β-catenin 信号通路并诱导炎症和脑细胞凋亡 (apoptosis) 导致斑马鱼脑血管及血脑屏障损伤,可用于脑血管疾病与心脏毒性的相关研究。

生物实验数据

生物活性 2-Hydroxyanthraquinone is a product generated from Anthracene (ANT) (MS-U94791) via photochemical oxidation; it induces cardiomyocyte ferroptosis by depleting GSH and inhibiting GPX4, leading to cardiac developmental malformations, and causes cerebrovascular and blood-brain barrier damage in zebrafish by downregulating the Wnt/β-catenin signaling pathway and inducing inflammation and brain cell apoptosis, making it applicable for research related to cerebrovascular diseases and cardiotoxicity.
体外研究
(In Vitro)

2-Hydroxyanthraquinone 可稳定结合斑马鱼 GPX4 蛋白,结合能为−8.3 kcal/mol,该结合由氨基酸残基 Pro-140、Lys-143 和 Arg-168 介导。

体内研究
(In Vivo)

2-Hydroxyanthraquinone (0.7-1.9 mg/L; 水体暴露; 6-60 h) 可通过同时诱导神经炎症并抑制 Wnt/β-catenin 信号通路,损害斑马鱼胚胎的脑血管和血脑屏障 (BBB) 发育,进而引发脑细胞凋亡性死亡及持续性运动行为异常。
2-Hydroxyanthraquinone (0.4-1.2 mg/L; 水体暴露; 6-96 h) 可通过铁死亡诱导斑马鱼胚胎产生浓度依赖性心脏发育毒性,包括心肌细胞增殖减少、氧化应激、脂质代谢紊乱、铁蓄积以及心脏结构/功能缺陷。
2-Hydroxyanthraquinone (300-400 µg/L; 经水暴露; 28 天) 可诱导成年斑马鱼产生心脏损伤,包括心室萎缩、心肌细胞变性、纤维化和空泡化。

Animal Model: wild-type (AB); transgenic lines Tg (kdrl:mCherry), Tg (mpeg1:GFP), Tg (fli:GFP), Tg (lyz:DsRed), Tg (elavl3:GFP) (embryos at 6 hours post-fertilization)
Dosage: 0.7 mg/L; 1.3 mg/L; 1.9 mg/L
Administration: waterborne; daily renewal; 6 hpf to 24 hpf or 60 hpf
Result: Reduced cerebrovascular area by ~40% relative to controls in medium (1.3 mg/L) and high (1.9 mg/L) dose groups at 24 hpf.
Reduced cerebrovascular area by 50% relative to controls in high dose group at 60 hpf; diminished head size by ~25% in high dose group at 60 hpf; shortened distance between intersegmental vessels at 60 hpf.
Downregulated genes involved in vascular/lymphatic development (itgb4, kdr, kdrl, vegfc, vegfa, flt4) at 60 hpf.
Increased brain microglia by ~40% relative to controls in high dose group.
Increased ROS content by over fourfold relative to controls in high dose group.
Upregulated pro-inflammatory cytokines (il1β, tnf-α, nf-κb, il6, nos2, rela) and downregulated anti-inflammatory il10.
Increased TUNEL-positive brain cells by ~twofold relative to controls in high dose group; upregulated p53 gene expression.
Increased BBB permeability in medium and high dose groups; altered expression of genes related to BBB development (spock1, abcc1, abcg2, abcb4, abcb5).
Reduced β-catenin protein expression to ~one-third of control levels; downregulated pathway target genes (lef1, β-catenin) and upregulated inhibitory genes (dkk1, wif1).
Reduced total movement distance, average swimming speed, movement time, and continuous movement duration by ~75% relative to controls in all dose groups; decreased activity frequency and cumulative activity duration, and increased immobility duration in a concentration-dependent manner.
Animal Model: wild-type (AB); transgenic Tg (myl7:GFP) (embryos, 6 hours post-fertilization)
Dosage: 0.4 mg/L; 0.8 mg/L; 1.2 mg/L
Administration: waterborne; continuous; 6 hpf to 96 hpf
Result: Caused concentration-dependent increases in zebrafish embryo mortality at 96 hpf.
Reduced body length to ~3500 μm (0.4 mg/L), ~3200 μm (0.8 mg/L), ~2500 μm (1.2 mg/L) vs control ~4000 μm at 96 hpf.
Increased yolk sac area at 96 hpf.
Enlarged pericardial area to ~25000 μm2 (0.4 mg/L), ~45000 μm2 (0.8 mg/L), ~65000 μm2 (1.2 mg/L) vs control ~15000 μm2 at 96 hpf.
Decreased heart rate over 20 seconds to ~45 beats (0.4 mg/L), ~35 beats (0.8 mg/L), ~30 beats (1.2 mg/L) vs control ~50 beats at 96 hpf.
Increased sinus venosus-bulbus arteriosus (SV-BA) distance to ~170 μm (0.4 mg/L), ~220 μm (0.8 mg/L), ~250 μm (1.2 mg/L) vs control ~120 μm in transgenic Tg (myl7:GFP) embryos at 96 hpf.
Reduced cardiomyocyte numbers and caused failed cardiac cyclization revealed by H&E staining.
Downregulated expression of cardiac developmental genes myl7, tbx2b, hand2, and upregulated gata4 and nppa.
Reduced cardiomyocyte proliferation by ~50% at 0.8 and 1.2 mg/L, with downregulated expression of proliferation-related genes cdk2, ccne1, and ccnd1.
Significantly elevated ROS levels in the heart, with downregulated expression of antioxidant genes nrf2, cat, sod, and gclm; decreased CAT and GSH activities, and increased SOD and MDA activities.
Increased cardiac lipid content revealed by Oil Red O staining, elevated total cholesterol (TC) at 1.2 mg/L, and dysregulated expression of lipid metabolism genes (scd, fasn, elovl4, elovl5 upregulated; cd36 downregulated).
Increased iron accumulation revealed by FerroOrange staining and tissue iron measurements, with dysregulated ferroptosis-related gene expression: gpx4, slc7a11, slc3a2 downregulated; acsl4 upregulated; iron metabolism genes fht1, tfr1, fpn1, dmt1 altered.
Significantly reduced pericardial area and restored gpx4 gene expression when co-exposed with 0.6 μM Fer-1 compared to 0.8 mg/L 2-Hydroxyanthraquinone alone.
Animal Model: wild-type (3-month-old adult)
Dosage: 300 µg/L; 400 µg/L
Administration: waterborne; daily; 28 days
Result: Caused ventricular atrophy with ventricular area ~650000 μm2 (300 µg/L), ~550000 μm2 (400 µg/L) vs control ~700000 μm2.
Induced partial cardiomyocyte degeneration in the 300 µg/L group revealed by H&E staining.
Induced partial fibrosis and vacuole formation in the 400 µg/L group revealed by H&E staining.
性状 固体
颜色 Yellow to green yellow

化学信息

分子量 224.22
分子式 C14H8O3
CAS No. 605-32-3
别名 2-羟基蒽醌

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (44.6 mM), Suspension.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.92 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (445.99 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.4599 mL22.2995 mL44.5991 mL111.4976 mL
5 mM0.8920 mL4.4599 mL8.9198 mL22.2995 mL
10 mM0.4460 mL2.2300 mL4.4599 mL11.1498 mL
15 mM0.2973 mL1.4866 mL2.9733 mL7.4332 mL
20 mM0.2230 mL1.1150 mL2.2300 mL5.5749 mL
25 mM0.1784 mL0.8920 mL1.7840 mL4.4599 mL
30 mM0.1487 mL0.7433 mL1.4866 mL3.7166 mL
40 mM0.1115 mL0.5575 mL1.1150 mL2.7874 mL
50 mM0.0892 mL0.4460 mL0.8920 mL2.2300 mL
60 mM0.0743 mL0.3717 mL0.7433 mL1.8583 mL
80 mM0.0557 mL0.2787 mL0.5575 mL1.3937 mL
100 mM0.0446 mL0.2230 mL0.4460 mL1.1150 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础